Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease

Neurochemistry International

Volumn 45, Issue 5, 2004, Pages 583-595

  Hynd, Matthew R ^a   Scott, Heather L ^a   Dodd, Peter R ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cerebral cortex; Excitotoxicity; Expression mRNA; Expression protein; Glutamate receptors; Human; Pathogenesis; Polyamines; Splice variants

Indexed keywords

AMINO ACID; BETA SECRETASE; CALCIUM; CATION; GLUTAMATE RECEPTOR; GLUTAMIC ACID; MAGNESIUM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; POLYAMINE; VACCINE; ZINC;

ALZHEIMER DISEASE; CALCIUM TRANSPORT; CENTRAL NERVOUS SYSTEM; CHOLINERGIC STIMULATION; COGNITION; EPILEPSY; HUMAN; HUNTINGTON CHOREA; HYPOXIA; ISCHEMIA; NERVE CELL; NERVE DEGENERATION; NERVE ENDING; NEUROPATHOLOGY; NEUROTRANSMISSION; OXIDATION REDUCTION REACTION; PATHOGENESIS; PH; PRIORITY JOURNAL; REVIEW; SYNAPSE;

ALZHEIMER DISEASE; ANIMALS; BIOGENIC POLYAMINES; EXCITATORY AMINO ACIDS; GLUTAMIC ACID; HUMANS; NERVE DEGENERATION; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPTIC TRANSMISSION;

EID: 3042693940     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2004.03.007     Document Type: Review

References (190)

1. Aizenman E., Lipton S.A., Loring R.H. Selective modulation of NMDA responses by reduction and oxidation. Neuron. 2:1989;1257-1263
2. Akazawa C., Shigemoto R., Bessho Y., Nakanishi S., Mizuno N. Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats. J. Comp. Neurol. 347:1994;150-160
3. Albin R.L., Greenamyre J.T. Alternative excitotoxic hypotheses. Neurology. 42:1992;733-738
4. Anderson, J.M., Hubbard, B.M., 1981. Age-related changes in Alzheimer's disease. Lancets, 1261.
5. Araneda R.C., Lan J.Y., Zheng X., Zukin R.S., Bennett M.V. Spermine and arcaine block and permeate N-methyl-D-aspartate receptor channels. Biophys. J. 76:1999;2899-2911
6. 13C -NMR spectroscopy Brain Res. 765:1997;218-227
7. Behe P., Stern P., Wyllie D.J., Nassar M., Schoepfer R., Colquhoun D. Determination of NMDA NR1 subunit copy number in recombinant NMDA receptors. Proc. R. Soc. B. 262:1995;205-213
8. Benveniste M., Mayer M.L. Multiple effects of spermine on N-methyl-D-aspartic acid receptor responses of rat cultured hippocampal neurones. J. Physiol. (Lond.). 464:1993;131-163
9. Blanpied, T.A., Boeckman, F.A., Aizenman, E., Johnson, J.W., 1997. Trapping channel block of NMDA-activated responses by amantadine and memantine. J. Neurophysiol. 77.
10. Bliss T.V.P., Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 361:1993;31-39
11. Bouvier M., Szatkowski M., Amato A., Attwell D. The glial cell glutamate uptake carrier countertransports pH-changing anions. Nature. 360:1992;471-474
12. Braak H., Braak E. Morphological changes in the human cerebral cortex in dementia. J. Hirnforsch. 32:1991a;277-282
13. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.). 82:1991b;239-259
14. Braak H., Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging. 16:1995;271-284
15. Braak H., Braak E., Bohl J. Staging of Alzheimer-related cortical destruction. Eur. Neurol. 33:1993;403-448
16. Brookmeyer R., Gray S., Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health. 88:1998;1337-1342
17. 2+ influx induced by β-amyloid peptide 25-35 in cultured hippocampal neurons results from network excitation. J. Neurobiol. 26:1995;325-338
18. Bussiere T., Giannakopoulos P., Bouras C., Perl D.P., Morrison J.H., Hof P.R. Progressive degeneration of nonphosphorylated neurofilament protein-enriched pyramidal neurons predicts cognitive impairment in Alzheimer's disease: stereologic analysis of prefrontal cortex area 9. J. Comp. Neurol. 463:2003;281-382
19. Canellakis E.S., Kyriakidis D.A., Rinehart C.A.J., Huang S.C., Panagiotidis C., Fong W.F. Regulation of polyamine biosynthesis by antizyme and some recent developments relating the induction of polyamine biosynthesis to cell growth. Biosci. Rep. 5:1985;189-204
20. Celano P., Baylin S.B., Casero R.A.J. Polyamines differentially modulate the transcription of growth-associated genes in human colon carcinoma cells. J. Biol. Chem. 264:1989;8922-8927
21. Chan P.H., Fishman R.A. Brain edema: induction in cortical slices by polyunsaturated fatty acids. Science. 201:1978;358-360
22. Chen N., Luo T., Raymond L.A. Subtype-dependence of NMDA receptor channel open probability. J. Neurosci. 19:1999;6844-6854
23. Chen N., Moshaver A., Raymond L.A. Differential sensitivity of recombinant N-methyl-D-aspartate receptor subtypes to zinc inhibition. Mol. Pharmacol. 51:1997;1015-1023
24. Choi D.W. Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci. 11:1988;465-469
25. Choi D.W. Methods for antagonizing glutamate neurotoxicity. Cerebrovasc. Brain Metab. Rev. 2:1990;105-147
26. Choi D.W. Excitotoxic cell death. J. Neurobiol. 23:1992;1261-1276
27. Christine C.W., Choi D.W. Effect of zinc on NMDA receptor-mediated channel currents in cortical neurons. J. Neurosci. 10:1990;108-116
28. Clements J.D., Lester R.A., Tong G., Jahr C.E., Westbrook G.L. The time course of glutamate in the synaptic cleft. Science. 258:1992;1498-1501
29. Collingridge G.L., Lester R.A.J. Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol. Rev. 40:1989;143-210
30. Constantine-Paton M. NMDA receptor as a mediator of activity-dependent synaptogenesis in the developing brain. Cold Spring Harb. Symp. Quant. Biol. 55:1990;431-443
31. Cowburn R.F., Hardy J.A., Roberts P.J., Briggs R. Regional distribution of pre- and postsynaptic glutamatergic function in Alzheimer's disease. Brain Res. 452:1988;403-407
32. Coyle J.T., Bird S.J., Evans R.H., Gulley R.L., Nadler J.V., Nicklas W.J., Olney J.W. Excitatory amino acid neurotoxins: selectivity, specificity, and mechanisms of action. Neurosci. Res. Prog. Bull. 19:1981;1-427
33. D'Amato R.J., Zweig R.M., Whitehouse P.J., Wenk G.L., Singer H.S., Mayeux R., Price D.L., Snyder S.H. Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann. Neurol. 22:1987;229-236
34. Danbolt N.C. Glutamate uptake. Prog. Neurobiol. 65:2001;1-105
35. Danysz W., Dyr W., Jankowska E., Glazewski S., Kostowski W. The involvement of NMDA receptors in acute and chronic effects of ethanol. Alcohol Clin. Exp. Res. 16:1992;499-504
36. Danysz W., Parsons A.C. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol. Rev. 50:1998;597-664
37. Delaere P., Duyckaerts C., Brion J.P., Poulain V., Hauw J.J. Tau, paired helical filaments and amyloid in the neocortex: a morphometric study of 15 cases with graded intellectual status in aging and senile dementia of Alzheimer type. Acta Neuropathol. (Berl.). 77:1989;645-653
38. Dingledine R., Borges K., Bowie D., Traynelis S.F. The glutamate receptor ion channels. Pharmacol. Rev. 51:1999;7-61
39. Dodd P.R. Excited to death: different ways to lose your neurones. Biogerontology. 3:2002;51-56
40. Dubinsky J.M. Intracellular calcium levels during the period of delayed excitotoxicity. J. Neurosci. 13:1993;623-631
41. Durand G.M., Bennett M.V., Zukin R.S. Splice variants of the N-methyl-D-aspartate receptor NR1 identify domains involved in regulation by polyamines and protein kinase C. Proc. Natl. Acad. Sci. U.S.A. 90:1993;6731-6735
42. Erecinska M., Silver I.A. Metabolism and role of glutamate in mammalian brain. Prog. Neurobiol. 35:1990;245-296
43. Evans D.A., Funkenstein H.H., Albert M.S., Scherr P.A., Cook N.R., Chown M.J., Hebert L.E., Hennekens C.H., Taylor J.O. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. J. Am. Med. Assoc. 262:1989;2551-2556
44. Foldes R.L., Rampersad V., Kamboj R.K. Cloning and sequence analysis of additional splice variants encoding human N-methyl-D-aspartate receptor (hNR1) subunits. Gene. 147:1994;303-304
45. Forsyth E., Ritzline P.D. An overview of the etiology, diagnosis, and treatment of Alzheimer disease. Phys. Ther. 78:1998;1325-1331
46. Francis P.T., Pangalos M.N., Bowen D.M. Animal and drug modelling for Alzheimer synaptic pathology. Prog. Neurobiol. 39:1992;517-545
47. 2+ in hippocampal slices. Neuropharmacology. 38:1999;1253-1259
48. Frick A., Zieglgansberger W., Dodt H.U. Glutamate receptors form hot spots on apical dendrites of neocortical pyramidal neurons. J. Neurophysiol. 86:2001;1412-1421
49. Gallagher M.J., Huang H., Grant E.R., Lynch D.R. The NR2B-specific interactions of polyamines and protons with the N-methyl-D-aspartate receptor. J. Biol. Chem. 272:1997;24971-24979
50. Geddes J.W., Chang-Chui H., Cooper S.M., Lott I.T., Cotman C.W. Density and distribution of NMDA receptors in the human hippocampus in Alzheimer's disease. Brain Res. 399:1986;156-161
51. Goldberg M.P., Weiss J.H., Pham P.C., Choi D.W. N-Methyl-D-aspartate receptors mediate hypoxic neuronal injury in cortical culture. J. Pharmacoi. Exp. Ther. 243:1987;784-791
52. 3H] glutamate binding J. Neurochem. 48:1987;543-551
53. Greenamyre J.T., Penney J.B. Jr., Young A.B., D'Amato C.J., Hicks S.P., Shoulson I. Alterations in L-glutamate binding in Alzheimer's and Huntington's diseases. Science. 227:1985;1496-1499
54. Greenamyre J.T., Porter R.H. Anatomy and physiology of glutamate in the CNS. Neurology. 44:1994;S7-S13
55. Ha H.C., Sirisoma N.S., Kuppusamy P., Zweier J.L, Woster P.M., Casero R.A.J. The natural polyamine spermine functions directly as a free radical scavenger. Proc. Natl. Acad. Sci. U.S.A. 95:1998;11140-11145
56. Ha H.C., Woster P.M., Yager J.D., Casero R.A.J. The role of polyamine catabolism in polyamine analogue-induced programmed cell death. Proc. Natl. Acad. Sci. U.S.A. 94:1997;11557-11562
57. Hanks S.D., Flood D.G. Region-specific stability of dendritic extent in normal human aging and regression in Alzheimer's disease. I. CA1 of hippocampus. Brain Res. 540:1991;63-82
58. Heller J.S., Canellakis E.S. Cellular control of ornithine decarboxylase activity by its antizyme. J. Cell. Physiol. 107:1981;209-217
59. Hess S.D., Daggett L.P., Crona J., Deal C., Lu C.C., Urrutia A., Chavez-Noriega L., Ellis S.B., Johnson E.C., Velicelebi G. Cloning and functional characterization of human heteromeric N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. 278:1996;808-816
60. Hess S.D., Daggett L.P., Deal C., Lu C.C., Johnson E.C., Velicelebi G. Functional characterization of human N-methyl-D-aspartate subtype 1A/2D receptors. J. Neurochem. 70:1998;1269-1279
61. Hollmann M., Boulter J., Maron C., Beasley L., Sullivan J., Pecht G., Heinemann S. Zinc potentiates agonist-induced currents at certain splice variants of the NMDA receptor. Neuron. 10:1993;943-954
62. Hollmann M., Heinemann S. Cloned glutamate receptors. Annu. Rev. Neurosci. 17:1994;31-108
63. Honey C.R., Miljkovic Z., MacDonald J.F. Ketamine and phencyclidine cause a voltage-dependent block of responses to L-aspartic acid. Neurosci. Lett. 61:1985;135-139
64. Hubbard B.M., Anderson J.M. Age-related variations in the neuron content of the cerebral cortex in senile dementia of Alzheimer type. Neuropathol. Appl. Neurobiol. 11:1985;369-382
65. Hynd M.R., Lewohl J.M., Scott H.L., Dodd P.R. Biochemical and molecular studies using human autopsy brain tissue. J. Neurochem. 85:2003;543-562
66. NMDA receptor NR1 subunit mRNA expression in Alzheimer's disease. J. Neurochem. 78:2001;175-182
67. Hynd M.R., Scott H.L., Dodd P.R. Quantitation of alternatively spliced NMDA receptor NR1 isoform mRNA transcripts in human brain by competitive RT-PCR. Brain Res. Prot. 11:2003a;52-66
68. Hynd M.R., Scott H.L., Dodd P.R. Quantitation of NMDA receptor NR2 mRNA transcripts in human brain by competitive RT-PCR. Brain Res. Prot. 11:2003b;67-79
69. Hynd, M.R., Scott, H.L., Dodd, P.R., 2004. Selective loss of NMDA receptor NR1 subunit isoforms in Alzheimer's disease. J. Neurochem. 89, 240-247.
70. Igarashi K., Kashiwagi K. Polyamines: mysterious modulators of cellular functions. Biochem. Biophys. Res. Commun. 271:2000;559-564
71. Ikonomovic M.D., Mizukami K., Warde D., Sheffield R., Hamilton R., Wenthold R.J., Armstrong D.M. Distribution of glutamate receptor subunit NMDAR1 in the hippocampus of normal elderly and patients with Alzheimer's disease. Exp. Neurol. 160:1999;194-204
72. 2+ of N-methyl-D-aspartate-activated channels. Biophys. J. 57:1990;1085-1090
73. Jones K.A., Baughman R.W. Both NMDA and non-NMDA subtypes of glutamate receptors are concentrated at synapses on cerebral cortical neurons in culture. Neuron. 7:1991;593-603
74. Kisvarday Z.F., Martin K.A., Freund T.F., Magloczky Z., Whitteridge D., Somogyi P. Synaptic targets of HRP-filled layer III pyramidal cells in the cat striate cortex. Exp. Brain Res. 64:1986;541-552
75. Klein R.C., Castellino F.J. Activators and inhibitors of the ion channel of the NMDA receptor. Curr. Drug Targets. 2:2001;323-329
76. Koh J.Y., Choi D.W. Selective blockade of non-NMDA receptors does not block rapidly triggered glutamate-induced neuronal death. Brain Res. 548:1991;318-321
77. Kohr G., Eckardt S., Luddens H., Monyer H., Seeburg P.H. NMDA receptor channels: subunit-specific potentiation by reducing agents. Neuron. 12:1994;1031-1040
78. Koltchine V., Anantharam V., Wilson A., Bayley H., Treistman S.N. Homomeric assemblies of NMDAR1 splice variants are sensitive to ethanol. Neurosci. Lett. 152:1993;13-16
79. Lapidus R.G., Sokolove P.M. Inhibition by spermine of the inner membrane permeability transition of isolated rat heart mitochondria. FEBS Lett. 313:1992;314-318
80. Laurie D.J., Seeburg P.H. Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. Eur. J. Pharmacol. 268:1994;335-345
81. Lawlor B.A., Ryan T.M., Schmeidler J., Mohs R.C., Davis K.L. Clinical symptoms associated with age at onset in Alzheimer's disease. Am. J. Psychiatr. 151:1994;1646-1649
82. Lazarewicz J.W., Wroblewski J.T., Costa E. N-Methyl-D-aspartate-sensitive glutamate receptors induce calcium-mediated arachidonic acid release in primary cultures of cerebellar granule cells. J. Neurochem. 55:1990;1875-1881
83. Lee V.M.Y., Balin B.J., Otvos L., Trojanowski J.Q. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science. 251:1991;675-678
84. Legendre P., Westbrook G.L. The inhibition of single N-methyl-D- aspartate-activated channels by zinc ions on cultured rat neurones. J. Physiol. 429:1990;429-449
85. 2+ transport. J. Biol. Chem. 261:1986;16478-16483
86. 2+ transport. Biochem. J. 286:1992;597-602
87. Lin L.H., Chen L.L., Harris R.A. Enflurane inhibits NMDA, AMPA, and kainate-induced currents in Xenopus oöcytes expressing mouse and human brain mRNA. FASEB J. 7:1993;479-485
88. Liu J.P., Zhang Q.X., Baldwin G., Robinson P.J. Calcium binds dynamin I and inhibits its GTPase activity. J. Neurochem. 66:1996;2074-2081
89. Lynch D.R., Guttmann R.P. NMDA receptor pharmacology: perspectives from molecular biology. Curr. Drug Targets. 2:2001;215-231
90. MacDermott A.B., Mayer M., Westbrook G.L., Smith S.J., Barker J.L. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. Nature. 321:1986;519-522
91. 3H] TCP binding in Alzheimer's disease Neurosci. Lett. 74:1987;371-376
92. Masu M., Tanabe Y., Tsuchida K., Shigemoto R., Nakanishi S. Sequence and expression of a metabotropic glutamate receptor. Nature. 349:1991;760-765
93. Masuko T., Kashiwagi K., Kuno T., Nguyen N.D., Pahk A.J., Fukuchi J., Igarashi K., Williams K. A regulatory domain (R1-R2) in the amino terminus of the N-methyl-D-aspartate receptor: effects of spermine, protons, and ifenprodil, and structural similarity to bacterial leucine/isoleucine/valine binding protein. Mol. Pharmacol. 55:1999;957-969
94. Masuko T., Kusama-Eguchi K., Sakata K., Kusama T., Chaki S., Okuyama S., Williams K., Kashiwagi K., Igarashi K. Polyamine transport, accumulation, and release in brain. J. Neurochem. 84:2003;610-617
95. Mattson M.P. Advances fuel Alzheimer's conundrum. Nat. Genet. 17:1997;254-256
96. Mattson M.P., Cheng B., Davis D.L., Bryant K., Lieberburg I., Rydel R.E. β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12:1992;376-389
97. Mattson M.P., Goodman Y. Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Res. 676:1995;219-224
98. Mayer M.L., Vyklicky L. Jr., Westbrook G.L. Modulation of excitatory amino acid receptors by group IIB metal cations in cultured mouse hippocampal neurones. J. Physiol. (Lond.). 415:1989;329-350
99. 2+ of NMDA responses in spinal cord neurones. Nature. 309:1984;261-263
100. McBain C.J., Mayer M.L. N-Methyl-D-aspartic acid receptor structure and function. Physiol. Rev. 74:1994;723-760
101. McDonald J.W., Johnston M.V. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res. Brain Res. Rev. 15:1990;41-70
102. McKee A.C., Kosik K.S., Kowall N.W. Neuritic pathology and dementia in Alzheimer's disease. Ann. Neurol. 30:1991;156-165
103. Meguro H., Mori H., Araki K., Kushiya E., Kutsuwada T., Yamazaki M., Kumanishi T., Arakawa M., Sakimura K., Mishina M. Functional characterization of a heteromeric NMDA receptor channel expressed from cloned cDNAs. Nature. 357:1992;70-74
104. 1-40. Brain Res. 958:2002;210-221
105. Mintzer J.E. The search for better noncholinergic treatment options for Alzheimer's disease. J. Clin. Psychiatr. 64(Suppl. 9):2003;18-22
106. Monaghan D.T., Bridges R.J., Cotman C.W. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 29:1989;365-402
107. 3H] TCP binding sites in Alzheimer's disease Neurosci. Lett. 73:1987;197-200
108. Monyer H., Burnashev N., Laurie D.J., Sakmann B., Seeburg P.H. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron. 12:1994;529-540
109. Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H., Burnashev N., Sakmann B., Seeburg P.H. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science. 256:1992;1217-1221
110. Mori H., Mishina M. Structure and function of the NMDA receptor channel. Neuropharmacology. 34:1995;1219-1237
111. Morrison L.D., Becker L., Kish S.J. S-Adenosylmethionine decarboxylase in human brain. Regional distribution and influence of aging. Brain Res. Dev. Brain Res. 73:1993;237-241
112. Morrison L.D., Cao X.C., Kish S.J. Ornithine decarboxylase in human brain: influence of aging, regional distribution, and Alzheimer's disease. J. Neurochem. 71:1998;288-294
113. Morrison L.D., Kish S.J. Brain polyamine levels are altered in Alzheimer's disease. Neurosci. Lett. 197:1995;5-8
114. Morrison L.D., Smith D.D., Kish S.J. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. J. Neurochem. 67:1996;1328-1331
115. Mountjoy C.Q., Roth M., Evans N.J., Evans H.M. Cortical neuronal counts in normal elderly controls and demented patients. Neurobiol. Aging. 4:1983;1-11
116. 3H] MK-801 binding in Alzheimer's disease Neurosci. Lett. 93:1988;225-230
117. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science. 258:1992;597-603
118. 3H] TCP) binding in human frontal cortex: decreases in Alzheimer-type dementia J. Neurochem. 54:1990;526-532
119. Nowak L., Bregestovski P., Ascher P., Herbet A., Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurones. Nature. 307:1984;462-465
120. Olney J.W. Excitatory transmitter neurotoxicity. Neurobiol. Aging. 15:1994;259-260
121. Palmer A.M. Neurochemical studies of Alzheimer's disease. Neurodegeneration. 5:1996;381-391
122. Palmer A.M., Burns M.A. Preservation of redox, polyamine, and glycine modulatory domains of the N-methyl-D-aspartate receptor in Alzheimer's disease. J. Neurochem. 62:1994;187-196
123. Paoletti P., Ascher P., Neyton J. High-affinity zinc inhibition of NMDA NR1-NR2A receptors. J. Neurosci. 17:1997;5711-5725
124. 2+. Neuron. 15:1995;1109-1120
125. Parsons C.G., Danysz W., Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology. 38:1999;735-767
126. Paschen W. Polyamine metabolism in different pathological states of the brain. Mol. Chem. Neuropathol. 16:1992;241-271
127. Pegg A.E. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res. 48:1988;759-774
128. Penney J.B. Jr., Maragos W.F., Greenamyre J.T., Debowey D.L., Hollingsworth Z., Young A.B. Excitatory amino acid binding sites in the hippocampal region of Alzheimer's disease and other dementias. J. Neurol. Neurosurg. Psychiatr. 53:1990;314-320
129. Perry T.L., Yong V.W., Bergeron C., Hansen S., Jones K. Amino acids, glutathione, and glutathtone transferase activity in the brains of patients with Alzheimer's disease. Ann. Neurol. 21:1987;331-336
130. Peters S., Koh J., Choi D.W. Zinc selectively blocks the action of N-methyl-D-aspartate on cortical neurons. Science. 236:1987;589-593
131. 3H] MK801 binding to the NMDA receptor complex, and its modulation in human frontal cortex during development and aging Brain Res. 588:1992;277-286
132. Pin J.-P., Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology. 34:1995;1-26
133. Premkumar L.S., Auerbach A. Identification of a high affinity divalent cation binding site near the entrance of the NMDA receptor channel. Neuron. 16:1996;869-880
134. Price D.L. New perspectives on Alzheimer's disease. Annu. Rev. Neurosci. 9:1986;489-512
135. Price D.L., Martin L.J., Sisodia S.S., Wagster M.V., Koo E.H., Walker L.C., Koliatsos V.E., Cork L.C. Aged non-human primates: an animal model of age-associated neurodegenerative disease. Brain Pathol. 1:1991;287-296
136. Procter, A.W., 2000. Abnormalities in non-cholinergic neurotransmitter systems in Alzheimer's disease. In: O'Brien, J., Ames, D., Burns A. (Eds.), Dementia, second ed. Edward Arnold, Oxford, pp. 433-442.
137. Procter A.W., Stirling J.M., Stratmann G.C., Cross A.J., Bowen D.M. Loss of glycine-dependent radioligand binding to the N-methyl-D-aspartate- phencyclidine receptor complex in patients with Alzheimer's disease. Neurosci. Lett. 101:1989a;62-66
138. 3H] MK-801 binding in Alzheimer's disease J. Neurochem. 53:1989b;698-704
139. Rafalowska J., Barcikowska M., Wen G.Y., Wisniewski H.M. Laminar distribution of neuritic plaques in normal aging, Alzheimer's disease and Down's syndrome. Acta Neuropathol. (Berl.). 77:1988;21-25
140. NMDA receptor is differentially responsive to conantokins in normal and Alzheimer disease human cerebral cortex. J. Neurochem. 81:2002;765-779
141. 3H] MK-801 binding to the N-methyl-D-aspartate receptor-ion channel complex by L-glutamate, glycine, and polyamines J. Neurochem. 51:1988;830-836
142. Reisberg B., Ferris S.H., de Leon M.J., Kluger A., Franssen E., Borenstein J., Alba R.C. The stage specific temporal course of Alzheimer's disease: functional and behavioral concomitants based upon cross-sectional and longitudinal observation. Prog. Clin. Biol. Res. 317:1989;23-41
143. Represa A., Duyckaerts C., Tremblay E., Hauw J.J., Ben-Ari Y. Is senile dementia of the Alzheimer type associated with hippocampal plasticity? Brain Res. 457:1988;355-359
144. Reynolds I.J., Miller R.J. Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc. Br. J. Pharmacol. 95:1988;95-102
145. Reynolds I.J., Miller R.J. Ifenprodil is a novel type of N-methyl-D-aspartate receptor antagonist: interaction with polyamines. Mol. Pharmacol. 36:1989;758-765
146. Riveros N., Fiedler J., Lagos N., Munoz C., Orrego F. Glutamate in rat brain cortex synaptic vesicles: influence of the vesicle isolation procedure. Brain Res. 386:1986;405-408
147. Rock D.M., Macdonald R.L. The polyamine spermine has multiple actions on N-methyl-D-aspartate receptor single-channel currents in cultured cortical neurons. Mol. Pharmacol. 41:1992a;83-88
148. Rock D.M., Macdonald R.L. Spermine and related polyamines produce a voltage-dependent reduction of N-methyl-D-aspartate receptor single-channel conductance. Mol. Pharmacol. 42:1992b;157-164
149. Rose F.C., 1988. The clinical diagnosis of early dementia. In: Rose F.C. (Ed.), Geriatrics Symposium on Dementia and Brain Ischaemia. Excerpta Medica Asia Ltd., Hong Kong, pp. 15-24.
150. Rothman S.M. The neurotoxicity of excitatory amino acids is produced by passive chloride influx. J. Neurosci. 5:1985;1483-1489
151. Rumbaugh G., Prybylowski K., Wang J.F., Vicini S. Exon 5 and spermine regulate deactivation of NMDA receptor subtypes. J. Neurophysiol. 83:2000;1300-1306
152. Sarhan S., Seiler N. On the subcellular localization of the polyamines. Hoppe-Seyler's Z. Biol. Chem. 370:1989;1279-1284
153. Scatton B. The NMDA receptor complex. Fundam. Clin. Pharmacol. 7:1993;389-400
154. Scott R.H., Sutton K.G., Dolphin A.C. Interactions of polyamines with neuronal ion channels. Trends Neurosci. 16:1993;153-160
155. Seiler, N., 1994. Formation, catabolism and properties of the natural polyamines. In: Jenner, P., Carter, C. (Eds.), Neuroscience Perspectives: The Neuropharmacology of the Polyamines. Academic Press, San Diego, CA, USA, pp. 1-30.
156. Shastry B.S., Giblin F.J. Genes and susceptible loci of Alzheimer's disease. Brain Res. Bull. 48:1999;121-127
157. Siman R., Noszek J.C. Excitatory amino acids activate calpain I and induce structural protein breakdown in vivo. Neuron. 1:1988;279-287
158. Smart T.G., Xie X., Krishek B.J. Modulation of inhibitory and excitatory amino acid receptor ion channels by zinc. Prog. Neurobiol. 42:1994;341-393
159. Sommer B., Seeburg P.H. Glutamate receptor channels: novel properties and new clones. Trends Pharmacol. Sci. 13:1992;291-296
160. Steele J.E., Palmer A.M., Stratmann G.C., Bowen D.M. The N-methyl-D-aspartate receptor complex in Alzheimer's disease: reduced regulation by glycine but not zinc. Brain Res. 500:1989;369-373
161. + channels, glutamate release, and NMDA receptors mediates delayed neurodegeneration through nitric oxide formation. J. Neurosci. 16:1996;5004-5013
162. Sugihara H., Moriyoshi K., Ishii T., Masu M., Nakanishi S. Structures and properties of seven isoforms of the NMDA receptor generated by alternative splicing. Biochem. Biophys. Res. Commun. 185:1992;826-832
163. Sullivan J.M., Traynelis S.F., Chen H.S., Escobar W., Heinemann S.F., Lipton S.A. Identification of two cysteine residues that are required for redox modulation of the NMDA subtype of glutamate receptor. Neuron. 13:1994;929-936
164. Sze C., Bi H., Kleinschmidt-DeMasters B.K., Filley C.M., Martin L.J. N-Methyl-D-aspartate receptor subunit proteins and their phosphorylation status are altered selectively in Alzheimer's disease. J. Neurol. Sci. 182:2001;151-159
165. Tabor C.W., Tabor H. Polyamines. Annu. Rev. Biochem. 53:1984;749-790
166. +. Proc. Natl. Acad. Sci. U.S.A. 87:1990;6445-6449
167. Tominaga-Yoshino K., Uetsuki T., Yoshikawa K., Ogura A. Neurotoxic and neuroprotective effects of glutamate are enhanced by introduction of amyloid precursor protein cDNA. Brain Res. 918:2001;121-130
168. Tomlinson, B.E., Corsellis, J.A.N., 1984. Ageing and the dementias. In: Hume Adams, J., Corsellis, J.A.N., Duchen, L.W. (Eds.), Greenfield's Neuropathology. Wiley, New York, pp. 951-1025.
169. Traynelis S.F., Burgess M.F., Zheng F., Lyuboslavsky P., Powers J.L. Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit. J. Neurosci. 18:1998;6163-6175
170. + sensitivity of excitatory amino acid receptor channels in rat cerebellar granule neurones. J. Physiol. 433:1991;463-727
171. Traynelis S.F., Hartley M., Heinemann S.F. Control of proton sensitivity of the NMDA receptor by RNA splicing and polyamines. Science. 268:1995;873-876
172. Trojanowski J.Q., Shin R.W., Schmidt M.L., Lee V.M. Relationship between plaques, tangles, and dystrophic processes in Alzheimer's disease. Neurobiol. Aging. 16:1995;335-345
173. Ulas J., Cotman C.W. Decreased expression of N-methyl-D-aspartate receptor 1 messenger RNA in select regions of Alzheimer brain. Neuroscience. 79:1997;973-982
174. Ulas J., Weihmuller F.B., Brunner L.C., Joyce J.N., Marshall J.F., Cotman C.W. Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study. J. Neurosci. 14:1994;6317-6324
175. Veldhuis J.D., Hammond J.M. Role of calcium in the modulation of ornithine decarboxylase activity in isolated pig granulosa cells in vitro. Biochem. J. 196:1981;795-801
176. Vignon J., Vincent J.P., Bidard J.N., Kamenka J.M., Geneste P., Monier S., Lazdunski M. Biochemical properties of the brain phencyclidine receptor. Eur. J. Pharmacol. 81:1982;531-542
177. 2+ antagonize NMDA and GABA responses of hippocampal neurons. Nature. 328:1987;640-643
178. Whetsell W.O.J., Shapira N.A. Neuroexcitation, excitotoxicity and human neurological disease. Lab. Invest. 68:1993;372-387
179. Williams K., Kashiwagi K., Fukuchi J., Igarashi K. An acidic amino acid in the N-methyl-D-aspartate receptor that is important for spermine stimulation. Mol. Pharmacol. 48:1995;1087-1098
180. 3H] MK-801 to the N-methyl-D-aspartate receptor: pharmacological evidence for the existence of a polyamine recognition site Mol. Pharmacol. 36:1989;575-581
181. Williams K., Zappia A.M., Pritchett D.B., Shen Y.M., Molinoff P.B. Sensitivity of the N-methyl-D-aspartate receptor to polyamines is controlled by NR2 subunits. Mol. Pharmacol. 45:1994;803-809
182. Winblad B., Poritis N. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine. Int. J. Geriatr. Psychiatr. 14:1999;135-146
183. Winfield D.A., Gatter K.C., Powell T.P. An electron microscopic study of the types and proportions of neurons in the cortex of the motor and visual areas of the cat and rat. Brain. 103:1980;245-258
184. 2+-permeable AMPA glutamate receptor channels. J. Gen. Physiol. 112:1998;623-636
185. Wu J., Anwyl R., Rowan M.J. β-Amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. Neuroreport. 6:1995;2409-2413
186. Yatin S.M., Yatin M., Varadarajan S., Ain K.B., Butterfield D.A. Role of spermine in amyloid β-peptide-associated free radical-induced neurotoxicity. J. Neurosci. Res. 63:2001;395-401
187. Yoneda Y., Ogita K. Neurochemical aspects of the N-methyl-D-aspartate receptor complex. Neurosci. Res. 10:1991;1-33
188. Zandi T. Changes in memory processes of dementia patients. Adv. Exp. Med. Biol. 282:1990;89-100
189. Zhang L., Zheng X., Paupard M.C., Wang A.P., Santchi L., Friedman L.K., Zukin R.S., Bennett M.V. Spermine potentiation of recombinant N-methyl-D-aspartate receptors is affected by subunit composition. Proc. Natl. Acad. Sci. U.S.A. 91:1994;10883-10887
190. Zimmer M., Fink T.M., Franke Y., Lichter P., Spiess J. Cloning and structure of the gene encoding the human N-methyl-D-aspartate receptor (NMDAR1). Gene. 159:1995;219-223